GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IO Biotech Inc (NAS:IOBT) » Definitions » YoY EBITDA Growth

IO Biotech (IO Biotech) YoY EBITDA Growth : 50.81% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is IO Biotech YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. IO Biotech's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 50.81%.

IO Biotech's EBITDA per Share for the three months ended in Mar. 2024 was $-0.30.


IO Biotech YoY EBITDA Growth Historical Data

The historical data trend for IO Biotech's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IO Biotech YoY EBITDA Growth Chart

IO Biotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
- 53.13 -1,394.24 84.53 19.37

IO Biotech Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.66 -11.99 18.16 40.70 50.81

IO Biotech YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

IO Biotech's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-1.94--2.406)/ | -2.406 |
=19.37 %

IO Biotech's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (Q: Mar. 2024 )
=(EBITDA per Share (Q: Mar. 2024 )-EBITDA per Share (Q: Mar. 2023 )) / | EBITDA per Share (Q: Mar. 2023 )) |
=(-0.303--0.616)/ | -0.616 |
=50.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IO Biotech YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of IO Biotech's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


IO Biotech (IO Biotech) Business Description

Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen N, DNK, DK-2200
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Executives
Brian Burkavage officer: Chief Accounting Officer C/O PASSAGE BIO, INC., ONE COMMERCE SQUARE, 39TH FLOOR, PHILADELPHIA PA 19103
Heidi Hunter director C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Partners Kurma 10 percent owner 24 RUE ROYALE, PARIS I0 75008
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Vivo Opportunity Fund Holdings, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Devin Whittemore Smith officer: General Counsel C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Vivo Capital Fund Ix, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Qasim Iftikhar Ahmad officer: Chief Medical Officer 1209 ORANGE STREET, WILMINGTON DE 19801
Amy Sullivan officer: Chief Financial Officer 38 OUTLOOK ROAD, SWAMPSCOTT MA 01907
David V Smith director 6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Lundbeckfond Invest A/s 10 percent owner SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100
Jack Nielsen director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vanessa Malier director 1209 ORANGE STREET, WILLMINGTON DE 19801
Claus A. Andersson director 1209 ORANGE STREET, WILMINGTON DE 19801

IO Biotech (IO Biotech) Headlines

From GuruFocus

IO Biotech Announces Appointment of New Chief Financial Officer

By Value_Insider Value_Insider 10-13-2022

IO Biotech Announces First Quarter Results for 2022

By PurpleRose PurpleRose 07-15-2022